Rates of Myeloid Neoplasms in Patients With
Unexplained Cytopenias
5.5”
.25”
G:.5”
Patients with unexplained cytopenias may never receive
a definitive diagnosis, or may eventually be classified
as having myelodysplastic syndromes (MDS, a myelo-
proliferative neoplasm [MPN] or, if their cytopenias
persist, as having idiopathic cytopenia of undetermined
significance [ICUS]). Adding mutational profiling to
the evaluation of patients with unexplained cytopenias
could help identify individuals who have or are at risk of
developing a myeloid malignancy, according to results
of a prospective cohort study published in Blood.
Lead author Luca Malcovati, MD, from the
Department of Molecular Medicine at the University
of Pavia in Italy, and colleagues looked for somatic mu-
tations in 40 genes known to be recurrently mutated
S:6.75”
in myeloid malignancies to determine their predic-
tive value for identifying patients with, or at high risk
of developing, a myeloid neoplasm. The researchers
found that carrying one or more of these somatic
mutations was associated with a high probability of de-
veloping a myeloid neoplasm during follow-up (hazard
ratio [HR] = 13.9; p<0.001).
“Mutation profiling on peripheral blood cells has a
high predictive value for identifying individuals at high
risk of developing MPNs,” Dr. Malcovati told ASH Clinical
News. “Mutation analyses may be a valuable complement
BOSULIF offers proven efficacy for patients with resistance or intolerance to prior therapy 2
In 2nd-line treatment, after imatinib (n=266 evaluable) a
34
%
of patients
53
%
of patients
achieved MCyR at 6 months achieved MCyR with a minimum
follow-up of 23 months
(95% CI: 28.2, 39.9)
Median duration of MCyR was not
reached at the time of analysis
53% of patients with MCyR maintained
MCyR for at least 18 months (with a
minimum follow-up of 23 months)
In 3rd-line treatment, after imatinib followed by nilotinib and/or dasatinib therapy (n=108 evaluable)
• 27% of patients achieved MCyR by 6 months (95% CI: 18.8, 36.2)
• 32% of patients achieved MCyR with a minimum follow-up of 13 months
• Median duration of MCyR was not reached at the time of analysis
— 51% of patients with MCyR maintained MCyR for at least 9 months (with a minimum follow-up of 13 months)
BOSULIF has a distinct safety and tolerability profile 2
Warnings and precautions include: gastrointestinal toxicity, myelosuppression, hepatic toxicity, fluid retention, renal toxicity, and embryofetal
toxicity. Please see Important Safety Information below for more detail.
Most common adverse reactions observed in >20% of
patients in the Phase 1/2 safety population (N=546)
Most common Grade 3/4 adverse reactions
observed in ≥10% of patients
All grades (%)
Grade 3/4 (%)
Nausea (46) Anemia (27) Anemia (13)
Thrombocytopenia (41) Pyrexia (26) Neutropenia (12)
Vomiting (39) Fatigue (24)
Abdominal pain (37)
a
Median duration of treatment was 22 months for evaluable patients.
MCyR=major cytogenetic response.
For more information on BOSULIF, visit www.BosulifHCP.com.
Embryofetal Toxicity: BOSULIF may cause fetal harm when administered
to a pregnant woman. Women of childbearing potential should be advised
of potential hazard to the fetus and to avoid becoming pregnant while
receiving BOSULIF.
Adverse Reactions: The most common adverse reactions observed in
greater than 20% of patients in the Phase 1/2 safety population (N=546)
were diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash,
anemia, pyrexia, and fatigue. The most common Grade 3/4 adverse reactions
and laboratory abnorma